Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CA242/CanAg Glycoform of MUC1 (CA242/CanAg-MUC1)
- Target
- CA242/CanAg-MUC1
- Molecular classification
- Glycoprotein, Mucin, Cell Surface Antigen
01
Overview
The CA242/CanAg glycoform of MUC1 is a cancer-associated, aberrantly glycosylated form of the transmembrane mucin protein MUC1. It presents the CA242 epitope, which is recognized by monoclonal antibodies like humanized C242 (HuC242). This specific glycoform is overexpressed in many epithelial cancers, particularly gastrointestinal tumors, making it a potential diagnostic biomarker and therapeutic target for antibody-based therapies and antibody-drug conjugates.
- Other names
- CanAg antigenCancer antigen CanAgCA242 epitope on MUC1
02
Mechanism of action
Antibody binding to CA242 epitope, targeted drug delivery via antibody-drug conjugate
03
Biological functions
Epithelial protectionBarrier functionCell-cell interactionImmune modulation
04
Disease associations
CancerGastrointestinal cancerEpithelial malignancies
05
Safety considerations
Off-target effects of antibody-drug conjugatesImmunogenicity of therapeutic antibodiesPotential for resistance development
06
Interacting drugs
Cantuzumab (HuC242)
1 more in the full profile.
07
Biomarkers
CA242 serum levelsMUC1 expressionCanAg expression
Beyond the preview
Go deeper on CA242/CanAg Glycoform of MUC1 (CA242/CanAg-MUC1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CA242/CanAg Glycoform of MUC1 (CA242/CanAg-MUC1).